Company intelligence / Profile preview

Aerie Pharmaceuticals

Durham, North Carolina, United Statesen.wikipedia.org ↗

Ownership: Private
Development stage: Commercial

Overview

Aerie Pharmaceuticals has two FDA-approved products—Rhopressa® and Rocklatan®—for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Its lead pipeline candidate, AR‑15512, recently met the primary endpoint in two Phase 3 trials for dry eye disease, positioning it for an FDA submission in 2024. The company also has clinical-stage sustained-release implants targeting retinal diseases such as DME and wet AMD[2][7][8].

Therapeutic areas: Ophthalmology
Modalities: Small moleculesSustained-release implants (drug-device combinations)
Industry: Biotech

Drug pipeline

5 assets

netarsudil + latanoprost

Commercial

Indications: Open-angle glaucoma, Ocular hypertension

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Aerie Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aerie Pharmaceuticals.

Explore the full profile